List of Perceptive IRT / RTSM Customers
London, W1K 3JB,
United Kingdom
Since 2010, our global team of researchers has been studying Perceptive IRT / RTSM customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Perceptive IRT / RTSM for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Perceptive IRT / RTSM for Clinical Trial Management include: Novartis, a Switzerland based Life Sciences organisation with 75883 employees and revenues of $51.72 billion, Sanofi, a France based Life Sciences organisation with 82878 employees and revenues of $47.74 billion, UCB, a Belgium based Life Sciences organisation with 9000 employees and revenues of $5.60 billion and many others.
Contact us if you need a completed and verified list of companies using Perceptive IRT / RTSM, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Perceptive IRT / RTSM customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Novartis | Life Sciences | 75883 | $51.7B | Switzerland | Perceptive Informatics | Perceptive IRT / RTSM | Clinical Trial Management | 2017 | n/a |
In 2017, Novartis implemented Perceptive IRT / RTSM to support its CAR T long term follow up study managed by Novartis Pharma Services AG. Perceptive IRT / RTSM provided interactive response technology for randomization and trial supply management across multiple European Union countries, and the CTIS trial record explicitly lists Perceptive Eclinical as the IRT provider with the study start recorded in 2017. This deployment is cataloged under Clinical Trial Management and addressed multi site supply logistics and patient tracking as core operational needs.
Implementation scope prioritized randomization workflows and RTSM inventory orchestration, with configuration of trial supply management modules to handle site dispensing, resupply triggers, and patient level tracking across participating sites. The architecture emphasized centralized IRT service provisioning to enable cross border supply routing and site level enrollment monitoring, using standard Clinical Trial Management functional terminology. Governance and operational oversight were tied to the sponsor trial record in CTIS and to Novartis Pharma Services AG for consistent multi country enrollment and supply process execution.
|
 |
Sanofi | Life Sciences | 82878 | $47.7B | France | Perceptive Informatics | Perceptive IRT / RTSM | Clinical Trial Management | 2019 | n/a |
In 2019, Sanofi implemented Perceptive IRT / RTSM to provide IRT/RTSM and eClinical support for Genzyme Corp.'s Phase III pediatric Gaucher disease study. The deployment, categorized under Clinical Trial Management, covered multi-country operations in France, Italy and Spain, and the CTIS record lists Perceptive Informatics Inc. and Perceptive Eclinical among third parties for the trial.
Perceptive IRT / RTSM managed core randomization workflows and supply related activities, including investigational product allocation and site level supply management, while supporting eClinical processes for patient enrollment and dosing assignment. Configuration work emphasized study specific randomization schemas, treatment arm assignment logic, and supply movement tracking consistent with Clinical Trial Management system capabilities.
Operational coverage focused on clinical operations and investigational product supply functions across sites in France, Italy and Spain, coordinating randomization events and resupply activities with site teams. The CTIS listing of Perceptive as a third party establishes vendor attribution in regulatory records, and Sanofi Perceptive IRT / RTSM Clinical Trial Management supported clinical operations and investigational product supply management for the multi-country Phase III study.
|
 |
UCB | Life Sciences | 9000 | $5.6B | Belgium | Perceptive Informatics | Perceptive IRT / RTSM | Clinical Trial Management | 2022 | n/a |
In 2022 UCB deployed Perceptive IRT / RTSM as the interactive response technology for a Phase II extension study in Parkinson's disease. The CTIS entry explicitly lists Perceptive as the IRT provider and records the study start in late 2022, indicating the Perceptive system was implemented around that time. Deployment covered 47 investigator sites across six European countries and was scoped to UCB Biopharma clinical operations for this specific study.
Perceptive IRT / RTSM was implemented to provide core randomization and inventory control capabilities. Configuration centered on RTSM functions including patient randomization workflows, drug kit assignment, site-level inventory tracking, and enrollment management, aligning with Clinical Trial Management functional workflows for clinical operations and clinical supply chain. The implementation emphasized study-level orchestration of randomization and supply release processes.
No external system integrations are documented in the source material, so the implementation narrative focuses on the Perceptive IRT / RTSM functional footprint within the study. Operational coverage was limited to the Phase II extension study across the six European countries and 47 sites, handling investigator site activation, subject enrollment routing, and investigational product inventory control. Governance is recorded at the study level through the CTIS filing, which names Perceptive as the IRT provider and ties the application to UCB Biopharma clinical trial operations.
|
Buyer Intent: Companies Evaluating Perceptive IRT / RTSM
- Raymond James & Associates, a United States based Banking and Financial Services organization with 19000 Employees
- Amgen, a United States based Life Sciences company with 28000 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||